title: Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.
abstract: Despite prolonged treatment with highly active antiretroviral therapy (HAART), infectious HIV-1 continues to replicate and to reside latently in resting memory CD4(+) T lymphocytes, creating a major obstacle to HIV-1 eradication. It is therefore not surprising to observe a prompt viral rebound after discontinuation of HAART. The nature of the rebounding virus, however, remains undefined. We now report on the genetic characterization of rebounding viruses in eight patients in whom plasma viremia was undetectable throughout about 3 years of HAART. Taking advantage of the extensive length polymorphism in HIV-1 env, we found that in five patients who did not show HIV-1 replication during treatment, the rebound virus was identical to those isolated from the latent reservoir. In three other patients, two of whom had been free of plasma viremia but had showed some residual viral replication, the rebound virus was genetically different from the latent reservoir virus, corresponding instead to minor viral variants detected during the course of treatment in lymphoid tissues. We conclude that in cases with apparent complete HIV-1 suppression by HAART, viral rebound after cessation of therapy could have originated from the activation of virus from the latent reservoir. In patients with incomplete suppression by chemotherapy, however, the viral rebound is likely triggered by ongoing, low-level replication of HIV-1, perhaps occurring in lymphoid tissues.
authors.affiliation: Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: C
authors.initials: C
authors.lastname: Chung
authors.forename: B S
authors.initials: BS
authors.lastname: Hu
authors.forename: T
authors.initials: T
authors.lastname: He
authors.forename: Y
authors.initials: Y
authors.lastname: Guo
authors.forename: A J
authors.initials: AJ
authors.lastname: Kim
authors.forename: E
authors.initials: E
authors.lastname: Skulsky
authors.forename: X
authors.initials: X
authors.lastname: Jin
authors.forename: A
authors.initials: A
authors.lastname: Hurley
authors.forename: B
authors.initials: B
authors.lastname: Ramratnam
authors.forename: M
authors.initials: M
authors.lastname: Markowitz
authors.forename: D D
authors.initials: DD
authors.lastname: Ho
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015752:Genes, env; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D008221:Lymphoid Tissue / Q000821:virology; D008297:Male; D012150:Polymorphism, Restriction Fragment Length; D012367:RNA, Viral / Q000302:isolation & purification; D012008:Recurrence; D019562:Viral Load; D017735:Virus Latency
chemical_list: D012367:RNA, Viral